Nasdaq:US$16.50 (-0.18) | HKEX:HK$26.55 (-0.10) | AIM:£2.65 (-0.03)
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2009-02-17

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn’s Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate